Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

AbbVie (ABBV) and IGI Therapeutics SA have entered into an exclusive licensing agreement for the latter’s lead ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

Regardless of the bearish sentiment prevailing across the Indian stock market today, Glenmark Pharma shares skyrocketed 16% ...

AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.

Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...